CCM
BBH icon

Catawba Capital Management’s VanEck Biotech ETF BBH Stock Holding History

Catawba Capital Management’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,750
Closed -$227K – 245
2015
Q1 		$227K Buy
+1,750
New +$220K 0.05% 230

Other funds holding BBH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
LFM
Lumina Fund Management New York $164M AUM 27.72% 1-Year Est. Return

Catawba Capital Management's BBH Position: Q2 2015 in Review

Catawba Capital Management sold out of VanEck Biotech ETF (BBH) in Q2 2015, closing a stake of 1,750 shares — an estimated $227K sold.

Catawba Capital Management first reported a position in BBH in Q1 2015 and held it in 1 quarter. The position peaked at $227K in Q1 2015. 81 funds tracked by Wall St. Rank hold BBH as of Q2 2015.

  • Catawba Capital Management reported no remaining VanEck Biotech ETF position as of Q2 2015 after selling out during the quarter.
  • Catawba Capital Management sold 1,750 VanEck Biotech ETF shares in Q2 2015, an estimated $227K.
  • Catawba Capital Management first reported a position in VanEck Biotech ETF in Q1 2015 and held it in 1 quarter.
  • Catawba Capital Management's VanEck Biotech ETF position peaked at $227K in Q1 2015.
  • 81 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2015.

Based on Catawba Capital Management's 13F filing for Q2 2015, filed 13 Jul 2015.